Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
By A. Fielding, S. Richards, R. Chopra, H. Lazarus, M. Litzow, G. Buck, I. J. Durrant, S. Luger, D. Marks, I. Franklin and 4 more. Blood, 2007
842 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/d62dcd7c8c808fd1377784519f7e7e0223b586c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- P. Kufer
- M. Goebeler
- M. Klinger
- S. Neumann
- T. Raff
- A. Viardot
- M. Schmid
- M. Stelljes
Citations in the corpus
- Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL) (2015, neutral): “1936-5233/15 http://dx.doi.org/10.1016/j.tranon.2015.07.003”
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. (2011, background): “Thus, despite an impressive 40% to 50% overall survival rate (reached over the last 10 years), refractory relapsed leukemia remains an unsolved therapeutic problem.(2) Therefore, therapies with an alternative mechanism of action are urgently needed.”